Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics granted 285,000 stock options to newly appointed Chief Commercial Officer Mark Sims as an employment inducement under Nasdaq Rule 5635(c)(4). The options have an exercise price of $10.03 per share, equal to the closing price on the grant date, and vest over four years contingent on continued service.
Key figures
- Exercise price
- 10.03
- Options granted
- 285000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.